Live Breaking News & Updates on Us Development Capabilities

Share this article
Share this article
PERTH, Australia and NEW YORK, Feb. 22, 2021 /PRNewswire/  PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development.
This year we are focused on transforming PYC Therapeutics into a U.S.-based, clinical-stage biotechnology company, including making significant advances in moving our three preclinical inherited ocular disease programs toward the clinic and leveraging our RNA platform to create new development candidates in both ocular and neurodegenerative diseases, said Sahm Nasseri, U.S. Chief Executive Officer of PYC Therapeutics. We have previously highlighted the importance of building out PYC in the U.S. and I am ....

Western Australia , Kaggen Ausma , Deborah Elson Matthew Deyoung , Sahm Nasseri , Leo Vartorella , Indianj Ophthalmol , Us Development Capabilities , Drug Administration , Us Management Team , Program Updates , Executive Officer , Sue Fletcher , Chief Scientific , Chief Business Officer , Chief Development Officer , Chief Financial Officer , West Coast , Cash Position , Ocular Diseases , Investigational New Drug , Nervous System , Cell Penetrating Peptides , Pyc Therapeutics , மேற்கு ஆஸ்திரேலியா , டெபோரா எல்சன் மேத்யூ டியூன் , எங்களுக்கு மேலாண்மை அணி ,